DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome

Launched by IMPERIAL COLLEGE LONDON · Apr 8, 2019

Keywords

ClinConnect Summary

The DAISy-PCOS Phenome Study is looking at how polycystic ovary syndrome (PCOS) affects women's health, particularly regarding hormone levels and metabolism. PCOS is a common condition that can cause irregular periods and challenges with getting pregnant, but it can also lead to serious health issues like type 2 diabetes and heart disease. This study aims to find out which women with PCOS are most at risk for these complications by examining their hormone levels, body composition, and medical history. By understanding the differences and similarities among participants, the researchers hope to identify groups of women who may need early intervention to prevent serious health problems.

To be eligible for this study, you should be a woman aged 18 to 70 who may have PCOS and able to give informed consent. However, if you are pregnant, breastfeeding, or have serious kidney or liver issues, you won't be able to participate. Participants will answer questions about their health, provide blood and urine samples, and undergo some measurements like body composition and blood pressure. This information will help researchers analyze hormone levels and metabolism to better understand PCOS and its risks. The study is currently recruiting, and your involvement could contribute valuable insights into managing this condition effectively.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with a suspected diagnosis of polycystic ovary syndrome
• • Age range 18-70 years
• • Ability to provide informed consent
• Exclusion Criteria:
• • Pregnancy or breastfeeding at the time of planned recruitment
• • History of significant renal (eGFR\<30) or hepatic impairment (AST or ALT \>two-fold above ULN; pre-existing bilirubinaemia \>1.2 ULN)
• • Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• • Participants who have participated in another research study involving an investigational medicinal product in the 12 weeks preceding the planned recruitment
• • Glucocorticoid use via any route within the last six months
• • Current intake of drugs known to impact upon steroid or metabolic function or intake of such drugs during the six months preceding the planned recruitment
• • Use of oral or transdermal hormonal contraception in the three months preceding the planned recruitment
• • Use of contraceptive implants in the twelve months preceding the planned recruitment